Predicted protein targets (top 17)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CDK2 | P24941 | 11/20 | 0.48 |
| ▸ | CCNA2 | P20248 | 10/20 | 0.48 |
| ▸ | CCNA1 | P78396 | 9/20 | 0.48 |
| ▸ | AURKA | O14965 | 6/20 | 0.48 |
| ▸ | PLK1 | P53350 | 4/20 | 0.48 |
| ▸ | TRPV1 | Q8NER1 | 1/20 | 0.45 |
| ▸ | CDK4 | P11802 | 2/20 | 0.44 |
| ▸ | CCND3 | P30281 | 2/20 | 0.44 |
| ▸ | CDK6 | Q00534 | 2/20 | 0.44 |
| ▸ | HDAC4 | P56524 | 1/20 | 0.43 |
| ▸ | HDAC6 | Q9UBN7 | 1/20 | 0.43 |
| ▸ | TTK | P33981 | 6/20 | 0.43 |
| ▸ | LMNA | P02545 | 1/20 | 0.42 |
| ▸ | THRB | P10828 | 1/20 | 0.42 |
| ▸ | IGF1R | P08069 | 1/20 | 0.41 |
| ▸ | PLK3 | Q9H4B4 | 1/20 | 0.41 |
| ▸ | PLK2 | Q9NYY3 | 1/20 | 0.41 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL15377272 | 0.89 | CDK2 (0.49) | CDK2CCNA2CCNA1AURKAPLK1 | |
| SCHEMBL12698365 | 0.89 | CDK2 (0.47) | CDK2CCNA2CCNA1AURKAPLK1 | |
| SCHEMBL17746016 | 0.84 | CCNA2 (0.54) | CDK2CCNA2CCNA1AURKAPLK1 | |
| SCHEMBL15377710 | 0.82 | CCNA2 (0.55) | CDK2CCNA2CCNA1AURKAPLK1 | |
| SCHEMBL15377759 | 0.80 | CDK2 (0.48) | CDK2CCNA2CCNA1AURKAPLK1 | |
| SCHEMBL15377350 | 0.78 | CDK2 (0.68) | CDK2CCNA2CCNA1AURKAPLK1 | |
| SCHEMBL12698369 | 0.76 | CDK2 (0.60) | CDK2CCNA2CCNA1AURKAPLK1 | |
| Trifluoroacetic Acid SCHEMBL15377887 | 0.75 | CDK2 (0.70) | CDK2CCNA2CCNA1AURKAPLK1 | |
| SCHEMBL17745986 | 0.75 | PLK1 (0.49) | CDK2CCNA2CCNA1AURKAPLK1 | |
| SCHEMBL15378222 | 0.74 | CCNA2 (0.53) | CDK2CCNA2CCNA1AURKAPLK1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 8 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2668188-B1 | TRICYCLIC DERIVATIVES, PROCESS FOR THEIR PREPARATION AND THEIR USE AS KINASE INHIBITORS | NERVIANO MEDICAL SCIENCES SRL (IT) | 2016-05-18 | — | — | EP | disclosed |
| US-8916577-B2 | Tricyclic derivatives, process for their preparation and their use as kinase inhibitors | NERVIANO MEDICAL SCIENCES S.R.L. (IT) | 2014-12-23 | — | — | US | disclosed |
| US-8916577-B2 | Tricyclic derivatives, process for their preparation and their use as kinase inhibitors | NERVIANO MEDICAL SCIENCES S.R.L. (IT) | 2014-12-23 | — | — | US | disclosed |
| US-8916577-B2 | Tricyclic derivatives, process for their preparation and their use as kinase inhibitors | NERVIANO MEDICAL SCIENCES S.R.L. (IT) | 2014-12-23 | — | — | US | disclosed |
| US-20130302416-A1 | TRICYCLIC DERIVATIVES, PROCESS FOR THEIR PREPARATION AND THEIR USE AS KINASE INHIBITORS | NERVIANO MEDICAL SCIENCES S.R.L. (IT) | 2013-11-14 | — | — | US | disclosed |
| US-20130302416-A1 | TRICYCLIC DERIVATIVES, PROCESS FOR THEIR PREPARATION AND THEIR USE AS KINASE INHIBITORS | NERVIANO MEDICAL SCIENCES S.R.L. (IT) | 2013-11-14 | — | — | US | disclosed |
| US-20130302416-A1 | TRICYCLIC DERIVATIVES, PROCESS FOR THEIR PREPARATION AND THEIR USE AS KINASE INHIBITORS | NERVIANO MEDICAL SCIENCES S.R.L. (IT) | 2013-11-14 | — | — | US | disclosed |
| WO-2012101029-A1 | TRICYCLIC DERIVATIVES, PROCESS FOR THEIR PREPARATION AND THEIR USE AS KINASE INHIBITORS | NERVIANO MEDICAL SCIENCES S.R.L. (IT) | 2012-08-02 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20130302416-A1 | TRICYCLIC DERIVATIVES, PROCESS FOR THEIR PREPARATION AND THEIR USE AS KINASE INHIBITORS | CDK1, MAP3K1, MAP3K20 | CDK2 16/4885CCNA2 239/4885CCNA1 244/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.